Italia markets close in 49 minutes

FTSE MIB
34.817,68
-581,14(-1,64%)
Dow Jones
40.050,71
+47,12(+0,12%)
Nasdaq
16.799,98
+114,02(+0,68%)
Nikkei 225
39.069,68
+282,30(+0,73%)
Petrolio
80,24
+0,18(+0,22%)
Bitcoin EUR
61.525,16
-153,23(-0,25%)

NVCR Sep 2024 20.000 put

OPR - OPR Prezzo differito. Valuta in USD.

Aggiungi a watchlist

2,2500

0,0000

(0,00%)

In data: 01:23PM EDT. Mercato aperto.

GlobeNewswire
Zai Lab and Novocure Announce LUNAR Phase 3 Clinical Trial Demonstrates Statistically Significant and Clinically Meaningful Extension in Overall Survival for Patients with Metastatic Non-Small Cell Lung Cancer After Platinum-Based Therapies
Tumor Treating Fields therapy together with standard of care provided a statistically significant and clinically meaningful 3-month improvement in median overall survival versus standard of care with no added systemic toxicities Tumor Treating Fields therapy together with immune checkpoint inhibitors resulted in an unprecedented 8-month improvement in median overall survival LUNAR is the first phase 3 clinical trial in more than seven years to show a significant extension in overall survival in